Heart Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enzyme Research
Research conducted at University of Texas has provided new information about enzyme research
June 21st, 2009
"The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD)," investigators in the United States report. "PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for degradation. jlr Individuals with loss-of-function mutations in PCSK9 have reduced plasma levels of LDL cholesterol and are protected from CHD; these observations have validated PCSK9 as a therapeutic target and suggested new approaches for the treatment and prevention of...
Source: Heart Disease Weekly (2009-06-21)
|
